E1089 Next Unicorns E11: insitro CEO Daphne Koller is optimizing drug discovery via machine learning

Follow Daphne: https://twitter.com/DaphneKoller

Check out insitro: https://insitro.com/

Follow Jason: https://linktr.ee/calacanis

Thanks to our partners LinkedIn Jobs (Get $50 off your first job post at https://linkedIn.com/unicorn), Zendesk (6 months free at https://www.zendesk.com/twist), and Vanta ($1K off your SOC 2 at https://www.vanta.com/twist).

0:00 Start

0:59 Jason intros Daphne Koller, CEO & Co-Founder of insitro

2:22 Daphne on the massive shift to remote education, what makes a great online course

10:02 Will college be changed forever?

15:35 Why Daphne started insitro

18:47 How machine learning plays into microbiology and drug discovery, why drug discovery is more expensive today than it has ever been

22:50 Who typically funds drug discovery companies? Why don't incumbent pharma companies utilize their data?

31:41 Which diseases are insitro going after first, and how are they approaching it with data?

38:30 Why we don't allow citizens to volunteer for early drug challenge trials for financial compensation & how COVID plays into that

49:20 How will current leading causes of death be solved over the coming decades?

55:30 Stem-cell research & breakthroughs, will human lifespans continue to increase?

1:00:10 GPT-3, are we in a simulation, is there a God?

1:05:40 What types of employees in insitro looking for?